Sihuan Pharmaceutical Holdings Group Valuation
Is 460 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 460 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 460 (HK$0.61) is trading below our estimate of fair value (HK$0.72)
Significantly Below Fair Value: 460 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 460?
Other financial metrics that can be useful for relative valuation.
What is 460's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥5.24b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.5x |
Enterprise Value/EBITDA | 69.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 460's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.8x | ||
1349 Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd | 2.6x | n/a | HK$6.5b |
1681 Consun Pharmaceutical Group | 2x | 12.3% | HK$5.6b |
1666 Tong Ren Tang Technologies | 1x | 8.7% | HK$7.5b |
3613 Beijing Tong Ren Tang Chinese Medicine | 5.7x | 13.6% | HK$8.6b |
460 Sihuan Pharmaceutical Holdings Group | 2.8x | 25.5% | HK$5.7b |
Price-To-Sales vs Peers: 460 is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (2.8x).
Price to Earnings Ratio vs Industry
How does 460's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price-To-Sales vs Industry: 460 is expensive based on its Price-To-Sales Ratio (2.8x) compared to the Hong Kong Pharmaceuticals industry average (1.5x).
Price to Sales Ratio vs Fair Ratio
What is 460's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.8x |
Fair PS Ratio | 4.6x |
Price-To-Sales vs Fair Ratio: 460 is good value based on its Price-To-Sales Ratio (2.8x) compared to the estimated Fair Price-To-Sales Ratio (4.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.